Procaterol HCL powder (81262-93-3) hplc≥98% – β-Agonist Wisepowder
Name Procaterol hydrochloride powder
Chemical name rel-8-Hydroxy-5-[(1R,2S)-1-hydroxy-2-[(1-methylethyl)amino]butyl]-2(1H)-quinolinone Hydrochloride, 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one hydrate hydrochloride
Synonyms Procaterol hydrochloride hemihydrate
Molecular Formula C16H25ClN2O4
Molecular Weight 344.836 g/mol
Melting Point 193-197° (dec)
InChI Key UIFLWWTUGCBILS-UHFFFAOYSA-N
Appearance White to Off-White Solid
Half Life ~3.83 hours
Solubility Soluble in water, formic acid and methanol, slightly soluble in ethanol (95) and practically insoluble in diethyl ether.
Storage Condition Refrigerator, Under Inert Atmosphere
Application Short-acting β2-adrenergic receptor agonist used to treat asthma.
Testing Document Available
03 Procaterol HCL powder (81262-93-3) General Description
Procaterol HCL powder is a specific and very potent β2-AR agonist. A vasodialator for long term treatment of asthma that may be administered orally or by aerosol inhalation for the treatment of dyspnea caused bybronchial asthma, chronic bronchitis, and pulmonary emphysema. The drug is not approved in the USA, but is available in Japan, Indonesia, and other countries worldwide.
Each mL of Procaterol HCl powder syrup contains Procaterol HCl hydrochloride5 mcg.Procaterol HCl syrup has a pH from 3.5 to 4.5. Procaterol HCl isProcaterol HCl hydrochloride hydrate (JAN) with a chemical name of 8-hydroxy-5-[(1RS,2SR)-1-hyrdoxy-2-[(1-methylethyl)amino]butyl]-quinolin-2-(1H)-one monohydrochloride hemihydrate. It has a molecular formula C16H22N2O3·HCl·½H2O and a molecular weight of 335.83.
Procaterol hydrochloride powder occurs as white to pale white yellowish white crystals or crystalline powder. The pH of its aqueous solution (1 in 100) is 4-5. Its aqueous solution (1 in 20) shows no optical rotation. It gradually changes in color when exposed to light.
04 Procaterol HCL powder (81262-93-3) History
Procaterol hydrochloride, a potent B,-adrenergic bronchodilator developedin Japan, was patented in 1974 and came into medical use in 1980. It was evaluated in a double-blind, placebo-controlled study for efJicacy and safety in 45 patients (ages18 to 55 yr) with chronic documented reversible airway disease. After a l-week placebo washout period, patients were administered either 0.05 mg or 0.10 mg of procaterol or placebo twice daily for 2 wk. Spirometric determinations, vital signs, and ECGs wereobtained at %, I, 2, 4, 6, and 8 hr after the first dose and at the sametime intervals after 1 and 2 wk of treatment. Patients recorded on a daily basis peak flow rates, asthma symptoms, need for supplemental aerosol, concurrent medications, and side effects. Spirometry results indicatedsign$cant improvement in pulmonary function with bothdoses of procaterol comparedwith placebo (P < 0.05). The larger dose was generally more effective. Bronchodilatation was evident % hr after dosing and peakedat 2 hr. At 8 hr after 0.10 mg of procaterol, FEV, wasstill above predose values. Daily peak Jlow rates were significantly higher with 0.10 mg than with 0.05 mg (P < 0.05) and placebo (P < 0.001).Tremor and nervousness were the most frequent side effects. They occurred in a dose-related frequency, were mild and transient, and occurred early in treatment. No signi$cant drug-related changes were noted in ECGs, heart rate, blood pressure, or clinical laboratory data. Procaterol hclwas found to be an effective, well-tolerated oral bronchodilator with a long duration of action, especially at 0.10 mg twice daily.